Study Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of dual specificity CD19 and CD22 CAR-T cells in patients with relapsed and refractory acute B lymphoblastic leukemia.
Want to learn more about this trial?
Request More InfoInterventions
Dual Specificity CD19 and CD22 CAR-T Cell ImmunotherapyDRUG
Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Second Affiliated Hospital of Xi'an Jiaotong University | Xi'an | Shaanxi | China |